Jason Westin/faculty.mdanderson.org
Jun 23, 2025, 06:59
Jason Westin: Mosun-Pola Is Superior to Chemotherapy for Patients with Aggressive Lymphoma
Jason Westin, Lead of the Lymphoma and Myeloma Service Line at MD Anderson Cancer Center, shared a post on LinkedIn:
“Big news from the 2025 International Conference on Malignant Lymphoma (ICML): Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma.
At the ICML meeting, I was honored to present, on behalf of an incredible team of global coauthors, the results of the Phase III SUNMO trial:
First positive Phase III trial in this space without conventional chemotherapy
59% reduction in risk of progression or death
Tripled median PFS
Doubled CR rate
Importantly, Mosun-Pola has the lowest CRS incidence and severity reported to date for a T-cell–engaging therapy:
96% of patients had no significant CRS
Fixed-duration, outpatient regimen
Combines a bispecific antibody with an ADC
This may open the door for broader patient access and outpatient delivery at more centers—helping more people with refractory or relapsed transplant-ineligible large B-cell lymphoma.
Excited for what’s ahead!”
More posts featuring Jason Westin.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 08:55
Jun 23, 2025, 08:55
Jun 23, 2025, 07:59